It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with a strong genetic component. Although next-generation sequencing (NGS) technologies have been successfully applied to gene identification in de novo ASD, the genetic architecture of familial ASD remains largely unexplored. Our approach, which leverages the high specificity and sensitivity of NGS technology, has focused on rare variants in familial autism. We used NGS exome sequencing in 26 families with distantly related affected individuals to identify genes with private gene disrupting and missense variants of interest (VOI). We found that the genes carrying VOIs were enriched for biological processes related to cell projection organization and neuron development, which is consistent with the neurodevelopmental hypothesis of ASD. For a subset of genes carrying VOIs, we then used targeted NGS sequencing and gene-based variant burden case-control analysis to test for association with ASD. Missense variants in one gene, CEP41, associated significantly with ASD (p = 6.185e−05). Homozygous gene-disrupting variants in CEP41 were initially found to be responsible for recessive Joubert syndrome. Using a zebrafish model, we evaluated the mechanism by which the CEP41 variants might contribute to ASD. We found that CEP41 missense variants affect development of the axonal tract, cranial neural crest migration and social behavior phenotype. Our work demonstrates the involvement of CEP41 heterozygous missense variants in ASD and that biological processes involved in cell projection organization and neuron development are enriched in ASD families we have studied.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
2 Sungkyunkwan University, Department of Health Sciences and Technology, SAIHST, Seoul, Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X)
3 University of Washington, Department of Genome Sciences, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
4 University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) ; University of Washington, Department of Medicine, Division of Medical Genetics, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
5 Sungkyunkwan University, Department of Health Sciences and Technology, SAIHST, Seoul, Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X) ; Samsung Medical Center, Division of Medical Science Research, Seoul, Korea (GRID:grid.414964.a) (ISNI:0000 0001 0640 5613)